Survival outcomes of management in metastatic gastric adenocarcinoma patients
HM Hu, HJ Tsai, HY Ku, SS Lo, YS Shan, HC Chang… - Scientific reports, 2021 - nature.com
Chemotherapy is generally considered as the main treatment for metastatic gastric
adenocarcinoma. The role of gastrectomy for metastatic gastric cancer without obvious …
adenocarcinoma. The role of gastrectomy for metastatic gastric cancer without obvious …
Survival outcomes of east Asian patients with advanced non‐small cell lung cancer treated with first‐line EGFR tyrosine kinase inhibitors: A network meta‐analysis of …
HC Chang, KT Huang, CC Tseng, YM Chen… - Thoracic …, 2023 - Wiley Online Library
Background The comparative efficacies of different generation tyrosine kinase inhibitors
(TKIs) in epidermal growth factor receptor (EGFR)‐mutated advanced non‐small cell lung …
(TKIs) in epidermal growth factor receptor (EGFR)‐mutated advanced non‐small cell lung …
Differential efficacy of tyrosine kinase inhibitors according to the types of EGFR mutations and agents in non-small cell lung cancer: a real-world study
TH Kim, JH Choi, MS Ahn, HW Lee, SY Kang, YW Choi… - BMC cancer, 2024 - Springer
Background Both first and second-generation EGFR-TKIs are recommended in advanced
NSCLC with common EGFR mutations. However, there are few data on the difference in …
NSCLC with common EGFR mutations. However, there are few data on the difference in …
Local Consolidative Therapy May Have Prominent Clinical Efficacy in Patients with EGFR-Mutant Advanced Lung Adenocarcinoma Treated with First-Line Afatinib
Simple Summary Afatinib is an irreversible epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitor (TKI) used to treat patients with advanced EGFR-mutant lung cancer. In this …
kinase inhibitor (TKI) used to treat patients with advanced EGFR-mutant lung cancer. In this …
Do patient characteristics affect EGFR tyrosine kinase inhibitor treatment outcomes? A network meta‐analysis of real‐world survival outcomes of East Asian patients …
HC Chang, CC Wang, CC Tseng, KT Huang… - Thoracic …, 2023 - Wiley Online Library
Background Despite the well‐established efficacies of tyrosine kinase inhibitors (TKIs) in
epidermal growth factor receptor (EGFR)‐mutated non‐small cell lung cancer (NSCLC) …
epidermal growth factor receptor (EGFR)‐mutated non‐small cell lung cancer (NSCLC) …
[HTML][HTML] Real-world data with afatinib in Spanish patients with treatment-naïve non-small-cell lung cancer harboring exon 19 deletions in epidermal growth factor …
S Agraso, M Lázaro, XL Firvida, L Santomé… - Cancer Treatment and …, 2022 - Elsevier
Background In clinical studies, first-line afatinib demonstrated efficacy in Del19-EGFR
NSCLC. Materials and Methods This prospective, non-interventional study assessed efficacy …
NSCLC. Materials and Methods This prospective, non-interventional study assessed efficacy …
Evaluating the Efficacy of EGFR-TKIs Combined With Radiotherapy in Advanced Lung Adenocarcinoma Patients With EGFR Mutation: A Retrospective Study
Y Wang, W Yu, J Shi, R Qiu, N Jiang… - … in Cancer Research …, 2022 - journals.sagepub.com
Objective: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have
been recommended as the first-line treatment for advanced lung adenocarcinoma with …
been recommended as the first-line treatment for advanced lung adenocarcinoma with …
[引用][C] COMPARISON OF THERAPEUTIC RESPONSES OF LUNG ADENOCARCINOMA PATIENTS RECEIVED TARGETED THERAPY
R SIMANJUNTAK, H ISKANDAR, NURA TABRI…